MPN Congress 2022

Leah SherwoodMyelofibrosis | April 12, 2023
A large analysis of real-world treatment outcomes in patients with myelofibrosis who were treated with ruxolitinib.
Leah SherwoodMyelofibrosis | April 12, 2023
Momelotinib led to “superior” symptom and spleen responses and transfusion independence rates compared to danazol.
Leah SherwoodMyeloproliferative Neoplasms | December 22, 2022
As TKIs have become available to patients, survival for those with CML has significantly improved but disparities.
Advertisement
Leah SherwoodMyeloproliferative Neoplasms | May 30, 2023
VERIFY, a phase III trial of the hepcidin mimetic rusfertide (PTG-300), is now enrolling patients with PV.
Leah SherwoodMyeloproliferative Neoplasms | December 27, 2022
IFN alpha-2 influences the regulation of several ECM genes involved in tissue remodeling.
Advertisement
Advertisement
Advertisement
Editorial Board